11 mar: Endelige vilkår for SDRO udstedt af Realkredit Danmark A/S
11 mar: Alm. Brand A/S - Ugentlig rapportering om aktietilbagekøb
11-03-2019 09:44:18

Share buy-back week 10/2019

Announcement

            

11 March 2019

Coloplast – transactions in connection with share buy-back programme

As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling up to DKK 1bn. This part of the programme of DKK500m is expected to take place from 25 February, 2019 to 23 August, 2019.

The buy-back programme will be structured in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Regulation 2016/1052, also referred to as the "Safe Harbour" rules, which ensure that the company is protected against violation of insider legislation in connection with the buyback programme.

The following transactions have been executed during the period 4 – 8 March 2019:

Date

Number of shares

Buying price

Amount DKK

4 March 2019

  6,000669.164,014,957.60

5 March 2019

  5,249672.923,532,154.98

6 March 2019

  4,055678.142,749,837.43

7 March 2019

  6,500680.044,420,258.70

8 March 2019

  7,579676.905,130,240.26

Accumulated until now under the programme

 

54,826

659.72

36,169,655.24

Henceforth, Coloplast owns 3,526,278 treasury B shares of DKK 1 equal to 1.63% of the company’s total share capital.

An overview showing the transaction data for the period 4 – 8 March 2019 is enclosed.

Kind regards,

Investor Relations

Coloplast A/S

Tel. +45 4911 1800

For further information, please contact

Investors and analyst

s                                           

Ellen Bjurgert

Vice President, Investor Relations

Tel. +45 4911 1800/+45 4911 3376

Email: dkebj@coloplast.com

Rasmus Sørensen

Sr. Manager, Investor Relations

Tel. +45 4911 1800/ +45 4911 1786

Email: dkraso@coloplast.com

                                                                                       

Press and the media                                               

Lina Danstrup

Sr. Media Relations Manager

Tel. 4911 2607

Email: dklina@coloplast.com

This announcement is available in a Danish and an English language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes ostomy care, urology and continence care and wound and skin care. We operate globally and employ about 12,000 people.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2019-03 All rights reserved Coloplast A/S, 3050 Humlebæk, Denmark.

Attachments

logo.png

Relateret indhold
17 apr - 
Onsdagens aktier: Coloplast faldt, men GN faldt mest
17 apr - 
FDA-påbud skærer 25 mio. dollar af toplinjen hos Colopl..
17 apr - 
Middag: Coloplast sætter sig mere end markedet efter FD..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Episode 15 - Lars Seier Christensen ser FC Porto som model for FCK

11-04-2019 15:15:13
I denne episode er finansmanden Lars Seier Christensen gæst i studiet hos Euroinvestors Lars Christensen til en snak om investeringer i sports- og fritidsindustrien med afsæt i Lars Seier Christensens nylige investering i Parken Sport & Entertainment - virksomheden bag fodboldklubben FC København.I samtalen fremhæver Lars Seier Christensen blandt andet den portugisiske fodklub FC Porto som en mode..

Aktier/tendens: Panalpina-tal kan give DSV-fokus i rolig handelsstart

17-04-2019 07:48:02
DSV kan komme i fokus onsdag, efter at schweiziske Panalpina, som den danske transportgigant er ved at overtage, fra morgenstunden har præsenteret regnskabstal, der var bedre end ventet blandt analytikerne.I årets første kvartal nåede Panalpina en omsætning på 1,49 mia. schweizerfranc, svarende til 9,8 mia. kr., hvor der blandt analytikere adspurgt af Bloomberg News var ventet en omsætning på 1,45..

Genmab-partner leverer bedre end ventet: Darzalex skuffer lidt

16-04-2019 12:58:48
Den amerikanske medicinalvirksomhed Johnson & Johnson, der samarbejder med danske Genmab omkring salg af kræftmidlet Darzalex, har leveret et bedre end ventet regnskab for første kvartal.Til gengæld ser det globale salg af Darzalex ud til at skuffe, da det i første kvartal endte på 629 mio. dollar. Til sammenligning havde Sydbanks senioranalytiker Søren Løntoft Hansen ventet et globalt salg på 660..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Coloplast B A/S 685.40 -1,7% Fald i aktiekurs
Coloplast 108.95 0,0% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. april 2019 20:48:27
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190410.2 - EUROWEB1 - 2019-04-19 20:48:27 - 2019-04-19 20:48:27 - 1 - Website: OKAY